AARDEX Group

March 2023 Medication Monitoring Matters Newsletter

Greetings and salutations! It’s time for the March issue of the Medication Monitoring Matters newsletter, where we delve into cutting-edge advancements in medication adherence monitoring.

In this edition, we’ll examine the potential downsides of Video Directly Observed Therapy (VDOT) as a monitoring solution and review adherence measurement trends for medicines approved by the European Medicines Agency between 2010 and 2020.

And if you’re considering attending the Chief Medical Officer/CMO Summit 360 in Boston next month, you will be delighted to know that we have secured an exclusive 20% discount code for you.

Let’s get started!

This Month’s Thoughts and Ideas

Literature Review Highlights Adherence Measurement Trends for EMA Approved Medicines

Article | Bernard Vrijens

Are you curious about the latest trends in medication adherence monitoring? In this blog post, we delve into a recent cross-sectional analysis of medication adherence measurement methods used in registration trials that supported the approval of new medicines by the European Medicines Agency (EMA) between 2010 and 2020. From outdated methods to emerging digital approaches, we discuss the key learnings from the analysis and what it means for the industry. 

From DOT to VDOT: An Evidence-Backed Review of Video Directly Observed Therapy

Article | Bernard Vrijens

In the quest to improve medication adherence, the promise of advanced tech and innovative approaches has captured the imagination of Sponsors and CROs alike. However, as with any solution, not all are created equal, and some may even erect barriers to optimal adherence. In this blog, we take a closer look at Video Directly Observed Therapy (VDOT) – a solution that some had hoped would be a silver bullet for medication adherence challenges. But is it all it’s cracked up to be?


Upcoming Events

Chief Medical Officer/CMO Summit 360, April 3-4, 2023, Boston, MA

The CMO Summit 360 is the largest gathering of biotech Chief Medical Officers across indications, modalities, company stages, professional experience levels, and geographic locations. This is the conference to connect with peers and develop the skills needed to succeed as a biotech Chief Medical Officer.

Join us at the event to hear from Bernard Vrijens, our Scientific Lead, and Ning Yu, Director of Technical Development at Biogen. Together, they will share their invaluable insights and lessons learned in implementing digital adherence monitoring in a late-stage drug development clinical trial.

But that’s not all; as event sponsors, we have an exclusive 20% discount code to share with our network. If you plan to join us, be sure to use the following code at checkout: AARDEX20.

We hope to see you there!

Share This Post

You may also like...

Breaking News

Enhancing Medication Adherence in Rare Disease Clinical Trials

In observance of Rare Disease Day, it is imperative to underscore the progressive strides within the domain of rare disease research. Rare diseases, characterized by their infrequent occurrence within the general populace, impose significant burdens not only on the affected